INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

Estimated average burden
OMB Number:			3235-0104
hours per response:			0.5

1. Name and Address of Reporting Person^*

Tsimerman Ronen

(Last)

(First)

(Middle)

7 HA'ESHEL ST., PO BOX 3163

(Street)

CAESAREA

3079504

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
IceCure Medical Ltd. [ ICCM ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares	177,949⁽¹⁾	D

**Table II - Derivative Securities Beneficially Owned**
**(e.g., puts, calls, warrants, options, convertible securities)**
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Share option (right to buy)	⁽²⁾	05/23/2027	Ordinary shares	83,610	0.79⁽³⁾	D
Share option (right to buy)	⁽⁴⁾	08/14/2028	Ordinary shares	75,000	2.09⁽⁵⁾	D
Share option (right to buy)	⁽⁶⁾	03/28/2029	Ordinary shares	4,549	2.27⁽⁷⁾	D
Share option (right to buy)	⁽⁸⁾	05/21/2029	Ordinary shares	16,000	1.79⁽⁹⁾	D
Share option (right to buy)	⁽¹⁰⁾	08/30/2030	Ordinary shares	28,833	1.56⁽¹¹⁾	D
Share option (right to buy)	⁽¹²⁾	04/28/2031	Ordinary shares	1,537	5.78⁽¹³⁾	D
Share option (right to buy)	⁽¹⁴⁾	01/12/2032	Ordinary shares	121,002	3.64⁽¹⁵⁾	D
Share option (right to buy)	⁽¹⁶⁾	03/23/2032	Ordinary shares	4,802	2.84⁽¹⁷⁾	D
Share option (right to buy)	⁽¹⁸⁾	02/19/2033	Ordinary shares	48,846	1.51⁽¹⁹⁾	D
Share option (right to buy)	⁽²⁰⁾	07/02/2034	Ordinary shares	127,322	0.92	D

Explanation of Responses:

1. Represents (i) 16,257 ordinary shares, (ii) 106,102 restricted share units ("RSUs") granted on July 2, 2024, 25% of which vest on July 29, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, and (iii) 55,590 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026.

2. A total of 95,555 options were granted on May 23, 2017, and vested in equal quarterly installments of 6.25% beginning May 1, 2017. As of March 18, 2026, 83,610 options are fully vested and 11,945 have been exercised into ordinary shares.

3. The options were granted with an exercise price of NIS 2.448 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $0.79 per share.

4. The options were granted on August 14, 2018, 25% of which vested on August 14, 2019, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 75,000 options are fully vested.

5. The options were granted with an exercise price of NIS 6.472 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.09 per share.

6. The options were granted on March 28, 2019, 25% of which vested on March 28, 2020, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 4,549 options are fully vested.

7. The options were granted with an exercise price of NIS 7.04 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.27 per share.

8. The options were granted on May 21, 2019, and vested in equal quarterly installments of 6.25% beginning on May 21, 2019. As of March 18, 2026, all 16,000 options are fully vested.

9. The options were granted with an exercise price of NIS 5.536 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.79 per share.

10. The options were granted on August 30, 2020, 25% of which vested on August 30, 2021, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 28,833 options are fully vested.

11. The options were granted with an exercise price of NIS 4.84 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.56 per share.

12. The options were granted on April 28, 2021, 25% of which vested on April 28, 2022, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 1,537 options are fully vested.

13. The options were granted with an exercise price of NIS 17.92 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $5.78 per share.

14. The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 121,002 options are fully vested.

15. The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $3.64 per share.

16. The options were granted on March 23, 2022, 25% of which vested on March 23, 2023, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 4,501 options are vested.

17. The options were granted with an exercise price of NIS 8.81 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.84 per share.

18. The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 36,634 options are vested.

19. The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share.

20. The options were granted on July 2, 2024, 25% of which vested on July 2, 2025, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 47,745 options are vested.

	/s/ Ronen Tsimerman	03/25/2026
	** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.